The Heads of Medicines Agencies (HMA), a European network of the heads of the national competent authorities, has approved Sensorion's volunturary harmonization procedure (VHP) application to initiate a phase 2 trial for SENS-401 for the treatment of sudden sensorineural hearing loss (SSNHL) in adults.
Swiss clinical-stage biopharmaceutical firm AC Immune has announced two clinical milestone events related to ACI-24, its anti-Abeta vaccine against Alzheimer's disease and Abeta-related cognitive decline in Down Syndrome.
Immunocore, a T Cell Receptor (TCR) biotechnology company, said that it has dosed the first patient in a phase I study of IMCnyeso, an ImmTAC molecule, as part of a collaboration with GlaxoSmithKline (GSK).
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals reported positive topline results for fasinumab from a phase 3 trial in patients with chronic pain from osteoarthritis (OA) of the knee or hip.
Novocure and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer.
Inovio Pharmaceuticals has dosed the first participant with PENNVAX-GP in a randomized clinical trial that will assess its ability to drive remission of HIV infection.
UK-based biopharmaceutical company Izana Bioscience has commenced a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis.
Samsung Bioepis said that it will soon start a phase 1 study to evaluate its pancreatitis drug SB26 in healthy volunteers.
Spark Therapeutics’ SPK-8011, an investigational gene therapy treatment for hemophilia A, was successful in reducing bleeding in a phase 1/2 trial, but also resulted in one of the participants getting hospitalized.
Summit Therapeutics said that its oral small molecule antibiotic ridinilazole was successful in preserving the gut microbiome of patients with C. difficile infection (CDI) during a phase 2 trial.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.